Medtronic in talks to exit neuroradiology business via sale of Micro Interventional Systems.
This article was originally published in The Gray Sheet
Executive Summary
MEDTRONIC MISSES TARGET WITH MICRO INTERVENTIONAL SYSTEMS: the company says it is in talks to exit the neuroradiology business by divesting MIS. Medtronic announced its decision to sell MIS less than two years after it acquired the firm in November 1995 for about $73 mil. in Medtronic stock ("The Gray Sheet" Nov. 6, 1995, p. 6). Medtronic is casting the divestiture as a way to enable it to refocus resources on further developing the company's coronary and peripheral vascular product business.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.